Key Takeaways CRSP rose 41.4% in three months primarily on CTX310 trial data and Casgevy momentum.CTX310 showed up to 86% LDL and 82% triglyceride reduction in early-stage studies.Casgevy sales hit $30.4M in Q2 2025, up 114% sequentially with 75+ centers activated.Shares of CRISPR Therapeutics (CRSP) have rallied 41.4% in the past three months, driven by encouraging data from a study of its in-vivo candidate, CTX310, as well as better-than-expected sales of Casgevy in the second quarter of 2025. Casgevy is ...